Tocofibrate | 50465-39-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Tocofibrate
• 英文别名: [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] 2-(4-chlorophenoxy)-2-methylpropanoate
• CAS: 50465-39-9
• 化学式: C₃₉H₅₉ClO₄
• 分子量: 627.3
• InChiKey: VPRFDABTJNLKKR-XHZSPPMBSA-N

物化性质

• 沸点：
  688.13°C (rough estimate)
• 密度：
  0.9284 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  13.7
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES<br/>[FR] DÉRIVÉS DE N-{[2-(PIPÉRIDIN-1-YL)PHÉNYL](PHÉNYL)MÉTHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACÉTAMIDE ET COMPOSÉS APPARENTÉS UTILISÉS EN TANT QUE MODULATEURS DE ROR-GAMMA POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：GENFIT

  公开号：WO2018138362A1

  公开（公告）日：2018-08-02

  The present invention provides e.g. N-[2-(piperidin-1-yl)phenyl] (phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.

  本发明提供了例如N-[2-(哌啶-1-基)苯基](苯基)甲基}-2-(3-氧代-3,4-二氢-2H-1,4-苯并噁嗪-7-基)乙酰胺衍生物和相关化合物，作为ROR-gamma调节剂，用于治疗例如自身免疫疾病、自身免疫相关疾病、炎症性疾病、代谢性疾病、纤维化疾病或胆汁淤积性疾病，例如关节炎和哮喘。
• [EN] RORGAMMA MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE RORGAMMA ET LEURS UTILISATIONS
  申请人：GENFIT

  公开号：WO2018138354A1

  公开（公告）日：2018-08-02

  The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases. (formula Ia)

  本发明提供了一种新型的化合物，其化学式为（Ia），这些化合物是RORgamma的调节剂。这些化合物以及包含它们的药物组合物是治疗任何疾病的合适手段，其中调节RORgamma具有治疗效果，例如在自身免疫疾病、自身免疫相关疾病、炎症性疾病、代谢性疾病、纤维化疾病或胆汁淤积性疾病中。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X4 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2020198537A1

  公开（公告）日：2020-10-01

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

  提供了一种通过接触MRGPR X4或向需要的受试者施用具有以下结构的化合物的有效量，从而对MRGPR X4进行调节，或更具体地用于治疗依赖于MRGPR X4的疾病，其中该结构为Formula (I): (I)或其药学上可接受的异构体、拉克酸盐、水合物、溶剂合物、同位素或盐，其中n、x、A、Q1、Q2、Z、R、R1、R2、R3、R4和R5的定义如本文所述。还提供了含有这些化合物的药物组合物，以及化合物本身。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• METHODS FOR IMPROVING COGNITIVE FUNCTION AND DECREASING HEART RATE
  申请人：DSM IP Assets B.V.

  公开号：EP2939671A1

  公开（公告）日：2015-11-04

  The present invention is directed to methods of improving cognitive function in subjects having age related cognitive decline or mild cognitive impairment and to methods of decreasing heart rate in a subject by administering dosage forms comprising docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA).

  本发明涉及改善与年龄相关的认知功能衰退或轻度认知障碍受试者的认知功能的方法，以及通过给药包含基本不含二十碳五烯酸（EPA）的二十二碳六烯酸（DHA）的剂型来降低受试者心率的方法。